<DOC>
	<DOCNO>NCT01146808</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy adefovir ( ADV ) prevent de novo Hepatitis B patient receive Hepatitis B core antibody ( HBcAb ) positive graft Hepatitis B Surface antigen ( HBsAg ) positive prior transplant ( Hepatitis B naive patient ) . The second objective evaluate efficacy accelerate vaccination Hepatitis B induce innate immunity , thereby obviate need life-long antiviral therapy .</brief_summary>
	<brief_title>Adefovir Plus Vaccination Transplant Patients Without Hepatitis B That Receive Core Antibody Positive Liver</brief_title>
	<detailed_description>The investigator conduct prospective , open-label study Hepatitis B naive patient receive HBcAb + liver adefovir prophylaxis post-transplant . At one year 18 month follow transplantation , study patient vaccinate standard Hepatitis B vaccine double dose monthly basis three month , point test Hepatitis B surface antibody ( HBsAb ) . Any study patient develop sufficient antibody response ( HBsAb &gt; 500 IU ) give option discontinue anti-viral treatment monitor setting .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Recipients evidence hepatitis B surface antigen , regardless HBcAb HBsAb status , : 1. receive liver transplantation hepatitis B core antibody positive ( HBsAg negative ) graft , 2. receive adefovir treatment post transplantation , 3. reach 18 month post transplantation time period . Recipients hepatitis B surface antigen positivity prior liver transplant . Grafts hepatitis B surface antigen positive patient . Previous intolerance ADV therapy Recipients pretransplant creatinine &gt; 1.6 mg/dL Patients young 21 year age Patients pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vaccination</keyword>
	<keyword>Immunocompromised Host</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Drug Resistance , Viral</keyword>
	<keyword>Resource Allocation</keyword>
</DOC>